o2h Ventures is delighted to announce a SEIS investment into Five Alarm Bio, a drug discovery company based in Cambridge, UK, that focuses on novel approaches to anti-aging with a broad potential for therapeutic application. FAB completed its seed investment round, raising over £500K to further its research to test new compounds. Prior to this, FAB received an Innovate UK grant of £360K in 2022 to initiate and support their research work.
Five Alarm Bio (FAB) is developing drug candidates that boost our ability to minimize the effects of aging in humans. Anti-aging science is becoming more relevant than ever. Aging is a major cause of almost all illnesses, and as the population ages, the impact of aging on healthcare and on our wider society is profound. The founders, three highly experienced entrepreneurs, identified a novel approach to addressing this problem and created FAB to discover therapies that target many age-related diseases and disabilities by targeting unexplored mechanisms of aging.
The investment was made from the ‘o2h Human Health SEIS Fund’ which aims to invest in very early-stage companies covering therapeutic drug opportunities or enabling drug discovery or services.
Sunil Shah, CEO of o2h Ventures, said: “We are delighted to have made this investment alongside Meltwind, Cambridge Angels, and Syndicate Room. The combination of the Scientific Depth of our CSO, William Bains, alongside the practical execution skills of the CEO, Janette Thomas, provides a great team to discover and develop new drugs for age-associated diseases”
Janette Thomas, CEO of Five Alarm Bio, said: “I am thrilled with the confidence shown by the investors in the ideas of the FAB team. I look forward to working with everyone to deliver this innovative and exciting program of research that will lead to much-needed treatments for people in the longer term”
About FAB
Anti-ageing science has enormous potential. Age-related diseases such as immune and neurodegenerative diseases are among the leading causes of disability, suffering and death, and a significant burden on health funding.
Five Alarm Bio is developing a small molecule approach to boost the body’s defense against aging, based on a new understanding of how the chemical damage associated with age accumulates in cells. In addition to a broad range of age-related diseases, Five Alarm Bio sees the relevance of its platform for cosmeceuticals.
Founded in 2016 by three experienced entrepreneurs, Five Alarm Bio is based near Cambridge, UK, and is carrying out research at the Babraham Campus.
For more details, please visit 5Alarmbio (fivealarmbio.com)
About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and Seed stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
Media Contact:
Juhi Shah
Marketing Executive
